Ingredients

New Tools Outline Advances for Continuous API Processing

June 02, 2018

From separation systems to reactor technology, new tools are increasing the feasibility of continuous API production.

IPEC-Americas Acquires Global Excipient Event

May 16, 2018

ExcipientFest has been acquired by IPEC and rebranded as Excipient World.

Porton Pharma Solutions and Codexis Partner on Biocatalysts

April 24, 2018

Porton will use biocatalyst technologies from Codexis to accelerate API development for clients.

Unlocking the Best Solution for API Sourcing

April 02, 2018

CMOs/CDMOs that are easy to work with, have demonstrated performance track records, and plan for the future are preferred.

A New Method for Risk Assessment of Pharmaceutical Excipients

March 02, 2018

This article describes a new, combined, quantitative method for assessing excipient risks that has been developed by the authors as one possible risk evaluation method.

Determination of Dermal PDE for Pharmaceutical Products

January 02, 2018

The authors offer recommendations for permissible daily exposures and concentration limits of elemental impurities for dermal drug products.

J&J and Zymeworks in Bispecific Antibody Pact Worth Nearly $1.5 Billion

November 16, 2017

As part of the deal, J&J’s Janssen will pay an upfront payment of $50 million to research, develop, and commercialize up to six bispecific antibodies.

Bayer in $1.5-Billion Deal with Loxo Oncology for Anti-Cancer Drugs

November 16, 2017

Bayer will make a $400-million upfront payment to develop and commercialize two anti-cancer compounds in Loxo Oncology’s portfolio.

Therapeutic Vaccines Target Cancer and Other Viral-Induced Diseases

November 15, 2017

The use of therapeutic vaccines presents a new way to manage diseases, such as cancer and sexually transmitted diseases.

WuXi and Pall Establish Continuous MAb Manufacture

November 13, 2017

The companies have established a joint laboratory to develop full continuous processing to manufacture high yields of monoclonal antibodies at reduced costs.